11月21日，拉芳家化跌5.09%，截至发稿，报22.21元/股，成交4733.55万元，换手率0.93%，总市值 50.02亿元。 截至发稿，季新星累计任职时间8年315天，现任基金资产总规模23.69亿元，任职期间最佳基金回报 163.78%， 任职期间最差基金回报-49.1%。 徐漫累计任职时间2年275天，现任基金资产总规模32.88亿元，任职期间最佳基金回报16.5%， 任职期 间最差基金回报-6.95%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，拉芳家化股份有限公司位于广东省汕头市龙湖区万吉工业区龙江路拉芳大厦，成立日期2001 年12月14日，上市日期2017年3月13日，公司主营业务涉及洗护类、护肤类、彩妆类产品的研发、生产 和销售。主营业务收入构成为：洗护类87.57%，其他9.52%，香皂2.84%，其他(补充)0.08%。 从拉芳家化十大流通股东角度 数据显示，华夏基金旗下1只基金位居拉芳家化十大流通股东。华夏内 ...

数据显示，华夏基金旗下1只基金位居拉芳家化十大流通股东。华夏内需驱动混合A（011278）三季度 新进十大流通股东，持有股数98.58万股，占流通股的比例为0.44%。根据测算，今日浮盈赚取约121.25 万元。 华夏内需驱动混合A（011278）成立日期2021年2月9日，最新规模13.65亿。今年以来收益0.27%，同类 排名7933/8138；近一年收益1.86%，同类排名7646/8055；成立以来亏损47.41%。 华夏内需驱动混合A（011278）基金经理为季新星、徐漫。 11月19日，拉芳家化涨5.21%，截至发稿，报24.85元/股，成交2.12亿元，换手率3.95%，总市值55.96亿 元。 资料显示，拉芳家化股份有限公司位于广东省汕头市龙湖区万吉工业区龙江路拉芳大厦，成立日期2001 年12月14日，上市日期2017年3月13日，公司主营业务涉及洗护类、护肤类、彩妆类产品的研发、生产 和销售。主营业务收入构成为：洗护类87.57%，其他9.52%，香皂2.84%，其他(补充)0.08%。 从拉芳家化十大流通股东角度 徐漫累计任职时间2年273天，现任基金资产总规模32.88亿元，任职期间最 ...

11月18日，拉芳家化涨5.63%，截至发稿，报24.19元/股，成交9408.52万元，换手率1.78%，总市值 54.48亿元。 截至发稿，季新星累计任职时间8年312天，现任基金资产总规模23.69亿元，任职期间最佳基金回报 163.78%， 任职期间最差基金回报-48.67%。 徐漫累计任职时间2年272天，现任基金资产总规模32.88亿元，任职期间最佳基金回报17.99%， 任职期 间最差基金回报-6.16%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从拉芳家化十大流通股东角度 数据显示，华夏基金旗下1只基金位居拉芳家化十大流通股东。华夏内需驱动混合A（011278）三季度 新进十大流通股东，持有股数98.58万股，占流通股的比例为0.44%。根据测算，今日浮盈赚取约127.16 万元。 华夏内需驱动混合A（011278）成立日期2021年2月9日，最新规模13.65亿。今年以来收益0.34%，同类 排名7949/8140；近一年收益 ...

Core Viewpoint - Marubi Biotech plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and international competitiveness after six years of being listed in A-shares [1][2]. Group 1: Company Actions and Financials - Marubi Biotech announced a delay of two years for its 344 million yuan investment in a "cosmetics intelligent manufacturing factory" project, citing sufficient existing production capacity [1][3]. - The company reported a cash dividend of 0.25 yuan per share, totaling 100 million yuan, on November 14 [1]. - As of the end of Q3 2025, Marubi had 1.592 billion yuan in cash and 413 million yuan in trading financial assets, despite the delay in its investment project [3][4]. Group 2: Performance Metrics - For the first three quarters of 2025, Marubi achieved a revenue of 2.45 billion yuan, a year-on-year increase of 25.51%, while net profit was 244 million yuan, up 2.13% [10][12]. - The company’s cash flow from operating activities increased significantly by 132.19% to 159 million yuan [5]. - Despite revenue growth, the company faced a decline in net profit excluding non-recurring items, which fell by 5.42% to 214 million yuan [10][12]. Group 3: Market Context and Strategic Implications - The trend of A-share companies seeking dual listings in Hong Kong is driven by supportive regulatory policies and a recovering market, with 87 IPOs in Hong Kong in 2025, a 55.36% increase year-on-year [7][8]. - Marubi's actions reflect a broader industry trend where companies are pursuing internationalization strategies amid structural challenges in the market [9][12]. - Analysts question the necessity of Marubi's Hong Kong listing given its substantial idle funds and ongoing delays in existing projects, suggesting a need for clarity on the strategic rationale behind the move [9][12].

Core Points - Lafang Home Products Co., Ltd. experienced a 5.1% increase in stock price, reaching 23.28 CNY per share, with a trading volume of 106 million CNY and a turnover rate of 2.07%, resulting in a total market capitalization of 5.243 billion CNY [1] - The company, established on December 14, 2001, and listed on March 13, 2017, specializes in the research, production, and sales of personal care products, with a revenue composition of 87.57% from hair care, 9.52% from other products, 2.84% from soap, and 0.08% from supplementary products [1] Shareholder Analysis - Among the top ten circulating shareholders of Lafang Home Products, Huaxia Fund's Huaxia Domestic Demand Driven Mixed A (011278) entered the list in the third quarter, holding 985,800 shares, which accounts for 0.44% of the circulating shares, with an estimated floating profit of approximately 1.1139 million CNY [2] - The fund was established on February 9, 2021, with a latest scale of 1.365 billion CNY, showing a year-to-date return of 2.1% and a one-year loss of 0.52%, ranking 7647 out of 8219 in its category [2] Fund Manager Performance - The fund manager of Huaxia Domestic Demand Driven Mixed A, Ji Xinxing, has a tenure of 8 years and 304 days, with a total fund asset size of 2.369 billion CNY, achieving a best return of 163.78% and a worst return of -48.2% during his tenure [3] - Co-manager Xu Man has a tenure of 2 years and 264 days, managing assets totaling 3.288 billion CNY, with a best return of 17.59% and a worst return of -5.3% during his management period [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported a revenue of 1.736 billion yuan in Q3 2025, a year-on-year decrease of 11.6%, with a net profit of 227 million yuan, down 23.6%. For the first three quarters, the total revenue was 7.098 billion yuan, an increase of 1.9%, and the net profit was 1.026 billion yuan, up 2.7% [9] - The company is focusing on enhancing profitability through cost reduction and efficiency improvements, with a gross margin of 74.7% in Q3 2025, an increase of 4.0 percentage points [9] - The company has signed a strategic cooperation agreement with West China Hospital to focus on mitochondrial anti-aging research, and its sub-brands OR and Yuanse Bota are showing strong growth [9] - The company is expected to achieve net profits of 1.615 billion yuan, 1.818 billion yuan, and 2.038 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 17.9, 15.9, and 14.2 [9] Financial Performance - The company's revenue for 2023 is projected at 8.905 billion yuan, with a growth rate of 39.5%. For 2024, revenue is expected to reach 10.778 billion yuan, with a growth rate of 21.0% [8] - The net profit for 2023 is estimated at 1.194 billion yuan, with a growth rate of 46.1%, and for 2024, it is projected to be 1.552 billion yuan, with a growth rate of 30.0% [8] - The company's EPS for 2025 is expected to be 4.08 yuan, with a PE ratio of 17.9 [8] Market Performance - The company's stock has shown a performance of -22% over the last 12 months compared to the CSI 300 index [4]

Core Insights - The A-share market experienced a decline last Friday, with the Shanghai Composite Index falling by 0.81% to 3954.79 points, and the Shenzhen Component Index dropping by 1.14% [2][8] - The trading volume in the A-share market was approximately 2.32 trillion RMB, with over 3500 stocks rising [2][8] - The biopharmaceutical, media, and retail sectors led the gains, while the telecommunications sector lagged [2][8] - The Hong Kong Hang Seng Index closed down 1.43%, and the Hang Seng Tech Index fell by 2.37% [2][8] - The U.S. stock indices saw slight increases, with the Dow Jones up 0.09%, S&P 500 up 0.26%, and Nasdaq up 0.61% [2][8] Important News - Wu Qing emphasized the importance of enhancing the inclusiveness and adaptability of the capital market, proposing six key tasks for the 15th Five-Year Plan period, including the development of direct financing and the cultivation of high-quality listed companies [3][9] Research Highlights - Recent tax policies have been introduced to boost consumption, with a focus on expanding the range of duty-free goods and supporting domestic products in duty-free stores [10][11] - The company reported a significant increase in revenue from its jewelry business, driven by new product launches and an expanding franchise channel [25][26] - The company’s gross margin improved due to product structure optimization, although increased marketing expenses have pressured net profit margins [15][16] - The company is actively reducing inventory to alleviate burdens and maintain shareholder returns during the adjustment period [21][22] - The company’s performance in the third quarter showed a notable decline in revenue and net profit, attributed to the deep adjustment in the liquor industry and proactive inventory reduction strategies [21][22] Investment Recommendations - The duty-free industry is expected to benefit from favorable policies, with an increase in consumer traffic to duty-free stores anticipated [14] - The jewelry business is projected to continue its rapid growth due to ongoing product innovation and channel expansion [27] - The company is maintaining a focus on shareholder returns, with a commitment to significant cash dividends despite industry challenges [23][24]

Core Insights - The company reported its Q3 2025 financial results, showing a mixed performance with revenue and profit pressures due to advanced promotional activities [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved operating revenue of 7.098 billion yuan, a year-on-year increase of 1.89%, and a net profit attributable to shareholders of 1.026 billion yuan, up 2.65% year-on-year [2]. - The gross margin for Q1-Q3 2025 was 73.69%, an increase of 3.62 percentage points year-on-year, while the net profit margin was 14.86%, up 0.19 percentage points year-on-year [2]. - In Q3 alone, the company reported revenue of 1.736 billion yuan, a decline of 11.63% year-on-year, and a net profit of 227 million yuan, down 23.64% year-on-year [2]. - The gross margin for Q3 was 74.68%, an increase of 3.96 percentage points year-on-year, but the net profit margin decreased by 2.01 percentage points to 13.19% [2]. Brand Performance - The main brand, Proya, maintains a solid industry position, while the Color Tang brand has been actively launching new products to expand its portfolio [3]. - In Q3 2025, skincare products generated revenue of 1.316 billion yuan, down 20.41% year-on-year; beauty makeup products remained stable at 236 million yuan; and hair care products saw a significant increase of 137.7%, reaching 179 million yuan [3]. - Proya ranked first in beauty category sales on Tmall during the first four hours of the Double Eleven sales event, and second in the beauty industry on Douyin during the first phase of the event [3]. Investment Outlook - The company is expected to continue steady growth in its main brand, with promising performance from its second and third-tier sub-brands, indicating a strong outlook for building a domestic beauty ecosystem [4]. - The earnings per share (EPS) forecasts for 2025-2027 are adjusted to 4.04, 4.52, and 5.02 yuan per share, with corresponding price-to-earnings (PE) ratios of 18, 16, and 15 times [4].

Core Viewpoint - Lafang Jiahua is a leading domestic brand in the washing and hair care industry, with a focus on product development, production, and sales across various beauty segments, including hair care, skin care, and cosmetics [1] Group 1: Business Performance - In Q3 2025, Lafang Jiahua reported revenue of 627 million yuan, ranking 8th among 8 companies in the industry, with the industry leader, Proya, generating 7.098 billion yuan [2] - The main business revenue composition includes hair care at 778 million yuan (87.57%), other income at 84.56 million yuan (9.52%), soap at 25.22 million yuan (2.84%), and other supplementary income at 716,700 yuan (0.08%) [2] - The net profit for the same period was 12.71 million yuan, also ranking 8th in the industry, with Proya leading at 1.055 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Lafang Jiahua's debt-to-asset ratio was 11.38%, a slight decrease from 11.54% year-on-year, significantly lower than the industry average of 25.15%, indicating strong solvency [3] - The gross profit margin for the period was 48.49%, an increase from 47.39% year-on-year, but still below the industry average of 66.60%, suggesting room for improvement in profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 11.38% to 18,400, with an average holding of 12,300 circulating A-shares, a decrease of 10.22% [5] - The top ten circulating shareholders include Huaxia Domestic Demand Driven Mixed A (011278), which is a new shareholder holding 985,800 shares [5] Group 4: Future Outlook - Analysts predict that Lafang Jiahua will see significant revenue growth, with forecasts of 984 million yuan, 1.094 billion yuan, and 1.240 billion yuan for 2025-2027, respectively, alongside an EPS of 0.29, 0.33, and 0.35 yuan [5] - The company is expected to enhance its marketing efforts, particularly on platforms like Douyin, and is exploring opportunities in the medical beauty sector [6] - Forecasted net profits for 2025-2027 are 72 million yuan, 92 million yuan, and 115 million yuan, reflecting substantial year-on-year growth [6]

证券代码：603983 证券简称：丸美生物 公告编号：2025-031 广东丸美生物技术股份有限公司 关于2025年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2025 年第三季度主要经营数据 披露如下： 二、2025 年第三季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 2025 年第三季度，公司主要产品的价格详见下表： | 主要产品 | 2024 | 年 7-9 | 月平均 | 2025 年 | 7-9 | 月平均 | 变动比率（%） | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 售价（元/支） | | | 售价（元/支） | | | | 眼部类 | | 99.33 | | | 151.81 | | 52.83 | | 护肤类 | | 99.45 | | | 103.95 | | 4 ...